Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bisoprolol + nebivolol refers to the combination or comparison of two distinct cardioselective beta-1 adrenergic receptor antagonists. Bisoprolol is a potent, highly selective beta-1 blocker without intrinsic sympathomimetic activity, primarily used for the management of hypertension and chronic heart failure. Nebivolol is a unique third-generation beta-1 selective blocker that also induces vasodilation through the L-arginine/nitric oxide pathway, mediated by beta-3 adrenergic receptor agonism. While both agents are approved for cardiovascular conditions, they are not typically formulated as a fixed-dose combination due to their overlapping pharmacological class. Clinical research, such as studies conducted by the Clinical Hospital Center Zemun, often focuses on head-to-head comparisons of these drugs to evaluate their respective impacts on echocardiographic parameters, hemodynamics, and endothelial function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bisoprolol + nebivolol.